Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 13;12(5):1223.
doi: 10.3390/cancers12051223.

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?

E Bridget Kim  1 , Andrew J Yee  2   3 , Noopur Raje  2   3
Affiliations
Review

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?

E Bridget Kim et al. Cancers (Basel). .

Abstract

The current standard of care for smoldering multiple myeloma (SMM) is observation until there is end-organ involvement. With newer and more effective treatments available, a question that is increasingly asked is whether early intervention in patients with SMM will alter the natural history of their disease. Herein, we review the evolving definition of SMM and risk stratification models. We discuss evidence supporting early intervention for SMM-both as a preventative strategy to delay progression and as an intensive treatment strategy with a goal of potential cure. We highlight ongoing trials and focus on better defining who may require early intervention.

Keywords: early intervention; prognostic features; risk stratification models; smoldering multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

E.B.K.: none; A.J.Y.: consulting for Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Sanofi, and Takeda; N.R.: consulting for Amgen, Bluebird Bio, BMS, Celgene, Janssen.

References

    1. Kyle R.A., Greipp P.R. Smoldering multiple myeloma. N. Engl. J. Med. 1980;302:1347–1349. doi: 10.1056/NEJM198006123022405. - DOI - PubMed
    1. Kyle R.A., Remstein E.D., Therneau T.M., Dispenzieri A., Kurtin P.J., Hodnefield J.M., Larson D.R., Plevak M.F., Jelinek D.F., Fonseca R., et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 2007;356:2582–2590. doi: 10.1056/NEJMoa070389. - DOI - PubMed
    1. Kyle R.A., Therneau T.M., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.F., Melton L.J., 3rd A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 2002;346:564–569. doi: 10.1056/NEJMoa01133202. - DOI - PubMed
    1. Mateos M.V., Hernandez M.T., Giraldo P., de la Rubia J., de Arriba F., Corral L.L., Rosinol L., Paiva B., Palomera L., Bargay J., et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): Long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1127–1136. doi: 10.1016/S1470-2045(16)30124-3. - DOI - PubMed
    1. Kapoor P., Rajkumar S.V. Smoldering Multiple Myeloma: To Treat or Not to Treat. Cancer J. 2019;25:65–71. doi: 10.1097/PPO.0000000000000350. - DOI - PubMed

LinkOut - more resources